Leicester spin-out MIP Diagnostics appoints CEO

Posted by er134 at Aug 05, 2015 11:35 AM |
Adrian Kinkaid appointed as CEO for spin-out company from the Leicester Biotechnology Group

Issued by Mercia Fund Management Limited on 5 August 2015

MIP Diagnostics, a University of Leicester spinout that develops molecularly imprinted polymers for research purposes, diagnostics and drug discovery, has begun the initial expansion of its business operations with the appointment of Adrian Kinkaid as CEO.  This follows a recent investment of £182,000 made by Mercia Fund Management.

Adrian will begin driving the technology into commercialisation, aiming to expand its uses into several exciting and disruptive research areas, including law enforcement, national security and food safety.  He will also work towards building a successful global marketing strategy with the development of a new website, including the creation of a portfolio of successful products.

Adrian has extensive experience in the life sciences sector, with particular expertise in affinity reagents, including antibodies, affirmers and aptamers.  He therefore has an in-depth understanding of the market and its competition, which will enable him to effectively market MIPS as a cost effective and high quality alternative to existing agents because of their robustness and speed of development.

Prior to joining MIP Diagnostics, Adrian worked as Chief Commercial Officer for Promexus, a protein biotherapeutics company based on affirmer technology exclusively licensed from Avacta Life Sciences.  Before that he was Strategic Market Development Leader for Abcam, the leading provider of research antibodies.

Adrian is also a Founding Member of ELRIG (European Laboratory Research and Innovation Group), a not-for-profit organisation that holds conferences and events for thought leadership in the life science and drug discovery communities.  Adrian served two terms as Chairman, during which time he established the flagship Drug Discovery event, which is now the leading conference of its kind in Europe.

Adrian Kinkaid said:

“As the new CEO of MIP Diagnostics, I have the opportunity to bring an exciting cutting edge technology into the market.  Furthermore, this technology has the potential to expand into different sectors, from monitoring food for contaminants, to protecting the population from the growing dangers of ‘legal highs’.  The technology has a number of advantages, not least of which are robustness, speed of development and the lack of ‘cold chain’ storage requirements.

It is a privilege to begin working with MIP Diagnostics, and I look forward to building a successful, dedicated team as we start expanding our impressive portfolio of products and services.”

Nicola Broughton, Investment Director of Technology Transfer, said:

“Adrian’s breadth of experience and exposure to different affinity reagents makes him more than capable of not only fully commercialising this disruptive technology, but also of moving it into exciting new sectors that cannot be explored by other agents on the market due to their complexity, slower speed of development and storage requirements.”

ENDS

For further information please contact:

Nicole Laffan

Communications Manager

Mercia Fund Management Limited

e nicolel@merciafund.co.uk

Or please visit www.merciafund.co.uk


About Mercia Fund Management

Mercia Fund Management, a wholly owned subsidiary  of Mercia Technologies PLC, is a leading investor in UK technology; specialising in the commercialisation of businesses with high growth potential across a range of technology driven sectors in which deep expertise is held.

Mercia can provide early stage, development and growth capital to enable investment in a wide range of opportunities whilst being strategically positioned to allocate follow-on capital to stars in the portfolio.

As sector specialists, Mercia’s value is not only in the pre-investment discovery, analysis and selection of high growth opportunities, but critically in the support of those companies post-investment. Investment directors have been directly involved in the financing, building and management of companies in their respective sectors, and work extensively with the executive management team of each investee company in order to drive value creation, control risk and deliver profitable exits.

Mercia Fund Management is wholly owned by Mercia Technologies PLC (www.merciatechnologies.com), which listed on AIM in December raising £70m. Mercia Technologies is focused on providing later stage direct investment to the emerging stars from the EIS and SEIS portfolio within the Mercia Growth Fund series to expand and ultimately exit these businesses.

The combination of EIS and SEIS funds under management and direct investment gives Mercia a unique venture capital model which, through follow-on funding, has the ability to back high-growth technology businesses anywhere from an early stage, through their growth journey and ultimately to a profitable exit.

Mercia Fund Management is an FCA authorised and regulated fund manager under FSMA (FRN: 524856).

www.merciafund.co.uk

About Leicester Biotechnology Group

Leicester Biotechnology Group (LBG) (originally Cranfield Biotechnology Centre) was established in 1981 at Cranfield University and moved to the University of Leicester in September 2013. LBG has a long track record of innovative work in the area of diagnostics and molecularly imprinted polymers and houses an inter-disciplinary team of chemists, engineers and biologists, all working together in a single state-of-the-art facility. This has come to harbour an environment rich in new research ideas that are applied to a wide variety of applications. Our worldwide reputation has been built up over 25 years, and maintained through links with numerous companies across the globe, engaged in the manufacture of diagnostic devices and polymers. This enables us to provide a unique insight into the materials and biosensor fields, not only from an academic viewpoint, but also through hands-on commercial experience. As a result of many years of working with Industrial clients, LBG has adopted a flexible and comprehensive portfolio of activities to assist businesses from concept through to product. An increasing role of the Group is to provide advice and information, which are difficult to obtain from conventional sources. Research is currently undertaken in five core areas. These are:

1. Bioanalytical chemistry - design of sensors and assays for clinical diagnostics, environment and food

2. Functional (smart) materials, polymers and MIPs

3. Computational design and molecular modelling

4.  Biotechnology and biopharmaceuticals

5.  Nanoparticles for diagnostics and therapeutic applications

The results of this research are described in more than 280 articles, books and patent applications which were published by the team.

The University of Leicester is a leading UK University committed to international excellence through the creation of world changing research and high quality, inspirational teaching. Ranked among the top one per-cent of universities in the world by the THE World University Rankings, the University is also committed to working with industry to generate business growth and find real applications for its leading research.

www2.le.ac.uk/about/facts

Share this page:

Older press releases

For press releases issued before 4 October 2010, please visit the old eBulletin site.

Get in touch

T: +44 (0)116 252 2160
E: press@le.ac.uk

The Press Office is open 9.00am-5.00pm, Monday to Friday.

For general enquiries about the University, contact the main switchboard on +44 (0)116 252 2522.